SIGN UP
LOG IN
S
02196
Shanghai Fosun Pharmaceutical (G…
14.34
0.28+1.99%Opening13:14 05/20 HKT
OPEN/PREV CLOSE14.080/14.060
TODAY RANGE14.080-14.360
VOL4.13M
MARKET CAP38.31B
52 WEEK RANGE11.520-19.500
AVG VOL (3M)5.14M
% TURNOVER0.15%
TURNOVER59.06M
P/E (TTM)12.038
% RANGE1.99%
EPS(TTM)1.191
P/E(FORWARD)11.351
P/B0.735
BVPS19.518
DIVIDEND0.300
P/S0.690
BETA--
DIV YIELD2.09%
FREE FLOAT MKT CAP7.76B
SHARES OUTSTANDING2.67B
NEXT EARNINGS08/26-09/02
FREE FLOAT541.29M
LOT SIZE500
EX-DIV DATE07/26/2024
News
Press Releases
Financial Reports
Profile
Reuters·05/09 10:46
SHANGHAI FOSUN PHARMA - APPROVAL FROM US FDA FOR CLINICAL TRIAL OF LBP-SHC4
Reuters·03/25 14:53
SHANGHAI FOSUN PHARMACEUTICAL GROUP FY OPERATING CASH FLOW RMB 4,477 MILLION
Reuters·02/26 12:46
BUZZ-Ardelyx rises as China approves kidney disease drug
Reuters·09/20/2024 08:44
SHANGHAI FOSUN PHARMACEUTICAL GROUP H1 NET INCOME RMB 1,550 MILLION
Reuters·06/24/2024 14:48
Shanghai Fosun Pharma to buy out Henlius Biotech, values it at $1.71 bln
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.